Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer. Mar, N., Friedlander, T. W., Hoimes, C. J., Flaig, T. W., Bilen, M., Balar, A., Henry, E., Srinivas, S., Rosenberg, J. E., Petrylak, D., Burgess, E., Merchan, J. R., Tagawa, S. T., Carret, A., Steinberg, J., Chaney, M. F., Milowsky, M. LIPPINCOTT WILLIAMS & WILKINS. 2020

View details for Web of Science ID 000560368309148